Etomidate a to z

14,253 views 35 slides Feb 23, 2016
Slide 1
Slide 1 of 35
Slide 1
1
Slide 2
2
Slide 3
3
Slide 4
4
Slide 5
5
Slide 6
6
Slide 7
7
Slide 8
8
Slide 9
9
Slide 10
10
Slide 11
11
Slide 12
12
Slide 13
13
Slide 14
14
Slide 15
15
Slide 16
16
Slide 17
17
Slide 18
18
Slide 19
19
Slide 20
20
Slide 21
21
Slide 22
22
Slide 23
23
Slide 24
24
Slide 25
25
Slide 26
26
Slide 27
27
Slide 28
28
Slide 29
29
Slide 30
30
Slide 31
31
Slide 32
32
Slide 33
33
Slide 34
34
Slide 35
35

About This Presentation

all information about etomidate


Slide Content

ETOMIDATE ( A to Z )

How many of you are using etomidate in your anesthesia practice ? Yes / No Will use of etomidate benefit in your anesthesia practice ? Yes / No If you want to learn new drugs in anesthesia then, will you use etomidate ? Yes / No

Lecture Outline History Mechanism of Action Effects on different body systems Pharmacokinetics Formulation of Drug Indications Contra-indications Adverse effects Doses in different situations Administration of drug Safety Information Etomidate & Adrenal Suppression References Case Discussions Take Home message

History Etomidate discovered by Janssen ( J & J ) Pharmaceuticals in 1964 at Belgium ( others drugs discovered are haloperidol, droperidol, fentanyl, sufentanyl, alfentanyl & carfentanyl ) First introduced as Anti-Fungal agent Introduced as IV Anesthetic agent ( due to potent sedative properties ) - In Europe 1972 - In USA 1983 - In India 2013 Brand name in India -Troymidate, Lipuro & Etomid Brand name outside India-Hospira, Amidate & hypnomidate

Mechanism of Action Carboxylated Imidazole agent Imidazole agent in IV anesthetic drugs R-1-(1-ethylphenyl)imidazole-5-ethyl ester Acts directly on the Gamma Amino Butyric Acid (GABA) receptor complex blocking neuroexcitation producing sedation/hypnosis/anesthesia without analgesia Acidic pH - 6.9, pKa – 4.2, poorly water soluble and soluble in 35 % propylene glycol

Effects on different body system * CNS – Decrease ICP, Cerebral Blood flow and Cerebral Metabolism But cerebral perfusion pressure maintained * CVS -- No or Minimal changes in Heart Rate, Blood Pressure and Cardiac Output No hemodynamic changes in response to pain No effect on Sympathetic tone * RS – Minimal changes in Respiratory Rate and Tidal Volume Slight elevation in arterial carbon dioxide tension (PaCO2) Transient apnea up to 90 seconds

Other Effects * No histamine release * Very rare allergic reactions * Hepatic and Renal blood flow decreased but clinically accepted

Pharmacokinetics Onset of Action : within 30 to 60 seconds Peak Effect : In 1 minute Duration : 3 to 5 minute and terminated by redistribution Protein Binding : 76 % Metabolism : Hepatic & Plasma Esterase Half-Life Distribution : 3 Minutes ( Anesthesia ) Half-Life Redistribution : 30 Minutes ( Sedation ) Half-Life Elimination : 3 hours ( Drowsiness )

Formulation of Drugs Available as Milky White Solution in 35 % Propylene Glycol Strength is 2mg/ml and 10 ml bulb is available in Indian market Outside India 20 ml (40 mg) Preloaded Syringes also available in 2mg/ml strength Now Etomidate is available with Medium and Long chain triglycerides (MCT/LCT) for painless entry in vein.

Indications As Sedation ( PSA) As Conscious Sedation As Hypnotic Agent Etomidate Interview in Lie Detector Test As Anesthetic Agent ( preferred in cardiac patients) In Rapid Sequence Intubation (RSI) In Cardio version as Premedication In ICU as infusion ventilated/ nonventilated patient As eSAM ( Etomidate Speech And Memory Test) ( To determine speech lateralization in patient prior to performing lobectomies to remove epileptogenic centers in brain )

Contra-Indications Proven sepsis with unstable hemodynamic patients Abnormally Low Blood Pressure even with Rx Decreased Function of the Adrenal Gland Hypersensitivity of Etomidate Pediatric Patients less than 10 years age ( but people have started using etomidate up to 2 years age with risk-benefit profile) In Pregnancy try to avoid as induction agent if other anesthetic agents are available In Geriatric Patients with caution

Adverse effects Transient Injection site pain up to 80 % patients Skeletal Muscle movements mainly myoclonic ( peripheral limb movements ) up to 30 % patients Opsoclonus ( uncontrolled eye movements ) Adrenal Suppression up to 10 % patients Hiccups Apnea up to 90 seconds Less frequently laryngospasm, nausea/vomiting, snoring, arrhythmia & increase in PaCO2

Doses in different situations For Sedation : 0.1 mg/kg up to three doses For G/A 0.3 to 0.4 mg/kg IV over 30-60 seconds In ICU : As continuous infusion 0.04 to 0.05 mg/kg/hr with continuous monitoring In Cushing Syndrome or law cortisol level pat . 0.2 mg/kg In Geriatric patients : 0.2 mg/kg In Pregnancy : 0.2 mg/kg In Pediatric Patients : 0.1 to 0.3 mg/kg

Administration of Drug Never dilute Etomidate with DW in same Syringe Preferably Large Vein for IV administration Preadministration of lidocaine if possible (2 ml) First dose to be completed within one arm-brain circulation (30 seconds ) All muscle relaxants, benzodiazepines, narcotics and ketamine are compatible with etomidate in same syringe except vecuronium and vit -c.

Safety Information * Etomidate causes drowsiness from 3 to 9 hours so Patients are instructed -Do note drive -Do not operative machinery -Do not drink alcohol for 24 hours Use with cautions in Geriatric and Pregnant pts. Less than 10 years children manufacturer has not recommended

Etomidate & Adrenal Suppression * Single dose etomidate causes measurable decrease in level of circulating cortisol But it never falls below physiological range Effect of low level remains up to 24 hours 100 to 200 mg hydrocortisone is preferable before etomidate administration In Sepsis and Septic Shocks there is already low level of cortisol so etomidate is not advisable for induction A fter three repeated doses etomidate shold be avoided

Best Anesthetic Agent for PSA PSA ( Procedural Sedation and Analgesia) The American College of Emergency Physicians (ACEP) defines procedural sedation as "a technique of administering sedatives or dissociative agents with or without analgesics to induce a state that allows the patient to tolerate unpleasant procedures while maintaining cardiorespiratory function. Procedural sedation and analgesia (PSA) is intended to result in a depressed level of consciousness that allows the patient to maintain oxygenation and airway control independently

Etomidate is most preferred drug in Hemodynamically unstable patients then any other anesthetic agents for induction of anesthesia

What journals say about Etomidate

Etomidate + Ketamine Mixture Most suitable mixture for short procedure Best combination for RSI in trauma and sepsis patients Good alternative in pedo patients compare to ketofol Both counter act each other adverse effects like myoclonus , nystagmus , injection site pain Dose is 0.1mg/kg etomidate + 1 mg/kg ketamine I have use almost in 50 short cases e.g. colonoscopy, upper GI scopy and circumcision

Case Discussion

1) Colonoscopy in triple vessel disease 2) Ludwig’s Angina in old age patient

Take Home Message The drug of choice in all types of cardiomyopathies When etomidate is used as sole anesthetic agent for induction or in any short procedure fentanyl group drugs or ketamin are must as premedication because of very short duration effect of etomidate In Pregnancy with Heart Disease etomidate is drug of choice In traumatic brain injury and severe trauma patients with unstable hemodynamic patient etomidate is preferred Universally accepted anesthetic agent in PSA and RSI